ArticleCureus2025
Cytokine Release Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although generally well tolerated, immune checkpoint inhibitors can occasionally lead to severe immune-related adverse events, including cytokine release syndrome (CRS), a condition resulting from excessive immune activation and cytokine secretion, specifically interleukin-6 (IL-6). We report the case of a 71-year-old male with stage IVB lung adenocarcinoma undergoing maintenance therapy with pembrolizumab and pemetrexed, who presented with an acute confusional state and fever unresponsive to antipyretics. An extensive infectious, neurological, and oncological workup was negative. Elevated serum IL-6 levels (270 pg/mL) supported the diagnosis of CRS. The patient was successfully treated with systemic corticosteroids, resulting in the resolution of fever and neurological symptoms. This case underscores the importance of early recognition and prompt management of CRS in patients receiving immune checkpoint inhibitors, highlighting corticosteroid therapy as an effective treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.